Gosset Cholinergic receptor Overview
Cholinergic receptors are **cell surface receptors** that mediate the actions of the neurotransmitter acetylcholine. They are divided into two main classes: **nicotinic acetylcholine receptors** (nAChRs), which are ligand-gated ion channels found at neuromuscular junctions and various neuronal sites, and **muscarinic acetylcholine receptors** (mAChRs), which are G protein-coupled receptors expressed throughout the central and peripheral nervous systems as well as in non-neural tissues. nAChRs mediate rapid synaptic transmission via ion flux, while mAChRs trigger slower, modulatory signaling cascades. Both receptor classes play key roles in autonomic nervous system function, cognitive processes, motor control, and numerous organ systems. Dysfunction or dysregulation is implicated in **neurodegenerative, neuropsychiatric, cardiovascular, inflammatory, and oncologic diseases**. Both receptor types are major therapeutic targets: *agonists*, *antagonists*, and *allosteric modulators* are used or being developed to treat conditions such as Alzheimer's disease, schizophrenia, cardiac arrhythmias, and inflammatory diseases[1][3][4][5][6][8].
Mechanism of Action
Agonist (direct receptor activation); Antagonist (direct receptor blockade); Allosteric modulation; Acetylcholinesterase inhibition (increases endogenous ACh at receptor)
Biological Functions
Disease Associations
Safety Considerations
- Peripheral cholinergic side effects (salivation, bradycardia, gastrointestinal upset)
- Central nervous system side effects (confusion, cognitive impairment)
- Muscle paralysis (nicotinic blockade)
- Addiction (nicotinic receptor agonists)
- Cardiovascular adverse effects (arrhythmia, hypotension)
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| Choline acetyltransferase (marks cholinergic neurons) |
| Acetylcholinesterase activity |
| Receptor subtype expression levels (e.g., M1, M2, α4β2 nAChR) |